title: [More with atrial fibrillation, anticoagulants since the coming of NOAK ].
abstract: Since the introduction of NOAC (non-vitamin K antagonist oral anticoagulants) in 2011 as thromboprophylactic treatment for patients with atrial fibrillation, AF, the number of patients with a diagnosis of atrial fibrillation has increased markedly in our health care registers. The proportion of patients treated with warfarin or NOAC has increased from 47 % to 58 % in 2013. The use of acetylsalicylic acid in patients is decreasing rapidly in patients with AF. NOAC are mostly prescribed by specialists and are mainly used in younger patients with lower CHA2DS2-VASc scores and lower risk for renal insufficiency and bleeding.
authors.affiliation: Karolinska Insitutet - Department of Medicine Solna Stockholm, Sweden Karolinska Insitutet - Department of Medicine Solna Stockholm, Sweden.
authors.forename: Tomas
authors.initials: T
authors.lastname: Forslund
authors.affiliation: Karolinska Institutet - clinical science and education, Södersjukhuset Stockholm, Sweden Karolinska University Hosptial - Clinical Pharmacology Solna, Sweden.
authors.forename: Mia
authors.initials: M
authors.lastname: von Euler
authors.affiliation: Karolinska University Hospital - Stockholm, Sweden - , Sweden.
authors.forename: Hans
authors.initials: H
authors.lastname: Johnsson
authors.affiliation: Karolinska Universitetssjukhuset - Koagulationsmottagningen, Hematologiskt centrum, Stockholm, Sweden karolinska Universitetssjukhuset - Koagulationsmottagningen, Hematologiskt centrum, Stockholm, Sweden.
authors.forename: Margareta
authors.initials: M
authors.lastname: Holmström
authors.affiliation: Stockholm County Council - HSF Stockholm, Sweden Stockholm County Council - HSF Stockholm, Sweden.
authors.forename: Björn
authors.initials: B
authors.lastname: Wettermark
authors.affiliation: Karolinska Institutet - Avdelningen för klinisk farmakologi Stockholm, Sweden - .
authors.forename: Paul
authors.initials: P
authors.lastname: Hjemdahl
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use*; D000991:Antithrombins / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000517:prevention & control; D001562:Benzimidazoles / Q000627:therapeutic use; D015331:Cohort Studies; D000069604:Dabigatran; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D004363:Drug Utilization; D065427:Factor Xa Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use; D018570:Risk Assessment; D000069552:Rivaroxaban; D013876:Thiophenes / Q000627:therapeutic use; D014859:Warfarin / Q000627:therapeutic use; D015091:beta-Alanine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D065427:Factor Xa Inhibitors; D009025:Morpholines; D011720:Pyrazoles; D011728:Pyridones; D013876:Thiophenes; D015091:beta-Alanine; C522181:apixaban; D014859:Warfarin; D000069552:Rivaroxaban; D000069604:Dabigatran; D001241:Aspirin